Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DermAtOmics-II: Optimizing Second-line Atopic Dermatitis Treatment
NCT06366932Phase 4Recruiting
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab + topical corticosteroids, tralokinumab + topical corticosteroids, upadacitinib + topical corticosteroids, baricitinib + topical corticosteroid and abrocitinib in atopic dermatitis (AD) (2 cohorts), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Percentage of patients with primary non-response to second-line treatment at 16 weeks. Started Sep 2023; status: recruiting.
02
Drugs
dupilumab + topical corticosteroidstralokinumab + topical corticosteroidsupadacitinib + topical corticosteroidsbaricitinib + topical corticosteroidabrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06366932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366932.